Gamida Cell Ltd (NASDAQ:GMDA) Short Interest Down 5.1% in November

Share on StockTwits

Gamida Cell Ltd (NASDAQ:GMDA) was the target of a significant decrease in short interest in November. As of November 15th, there was short interest totalling 44,800 shares, a decrease of 5.1% from the October 31st total of 47,200 shares. Currently, 0.4% of the company’s stock are sold short. Based on an average daily trading volume, of 30,300 shares, the days-to-cover ratio is presently 1.5 days.

A number of large investors have recently made changes to their positions in the business. Millennium Management LLC grew its stake in Gamida Cell by 4.6% in the 3rd quarter. Millennium Management LLC now owns 69,077 shares of the company’s stock valued at $299,000 after purchasing an additional 3,017 shares during the period. Royal Bank of Canada bought a new position in Gamida Cell in the 2nd quarter valued at $71,000. Phoenix Holdings Ltd. bought a new position in Gamida Cell in the 3rd quarter valued at $121,000. Bank Hapoalim BM bought a new position in Gamida Cell in the 2nd quarter valued at $195,000. Finally, EcoR1 Capital LLC bought a new position in Gamida Cell in the 2nd quarter valued at $265,000. Hedge funds and other institutional investors own 23.99% of the company’s stock.

Shares of Gamida Cell stock opened at $5.12 on Monday. The stock has a fifty day simple moving average of $4.85 and a 200 day simple moving average of $5.00. Gamida Cell has a 12-month low of $2.93 and a 12-month high of $15.41. The company has a market capitalization of $121.11 million and a P/E ratio of -0.49. The company has a current ratio of 7.61, a quick ratio of 7.60 and a debt-to-equity ratio of 0.09.

Gamida Cell (NASDAQ:GMDA) last announced its quarterly earnings data on Wednesday, November 13th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.07. On average, analysts predict that Gamida Cell will post -1.12 EPS for the current year.

Several equities research analysts recently issued reports on GMDA shares. JMP Securities started coverage on Gamida Cell in a report on Friday, September 20th. They set an “outperform” rating and a $16.00 price target for the company. Oppenheimer set a $18.00 price target on Gamida Cell and gave the stock a “buy” rating in a report on Wednesday, August 7th. Finally, Zacks Investment Research downgraded Gamida Cell from a “buy” rating to a “hold” rating in a report on Wednesday, October 9th.

About Gamida Cell

Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.

Read More: Do equity income investments outperform growth and income investments?

Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.